menu

NEWS

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood’s Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression March 6, 2024 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature. The study evaluated miR-Blood, Hummingbird Diagnostics’ small RNA expression dataset for eleven major components of human peripheral blood. A highly comprehensive blood cell type expression atlas for small RNAs, miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression, enabling a deeper understanding of blood and immune...

READ MORE
Hummingbird Diagnostics GmbH to Unveil Pioneering Alzheimer’s Disease Biomarker Research at CTAD Conference

October 25, 2023 07:30 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in blood-based small RNA detection and characterization, today announced the presentation of groundbreaking research data at the Clinical Trials in Alzheimer’s Disease (CTAD)conference in Boston. “Our mirCator platform sets new standards for blood-based small RNA handling, processing, analysis, and characterization”Tweet this The company has applied its state-of-the-art “mirCator” platform to answer critical questions related to Alzheimer’s disease. AI-powered mirCator provides deep insights through the integrated analysis of both disease & immune system derived small RNAs that was initially deployed for early detection of lung cancer (published...

READ MORE
Lung Cancer Data Heralds Shift for Hummingbird Diagnostics to Focus on Early Detection

Aug 01, 2023 | Molika Ashford genomeweb NEW YORK – German RNA-based testing firm Hummingbird Diagnostics is making strides to develop a microRNA assay for the early detection of lung cancer. Last month, the company published promising data on the development of an 18-miRNA signature dubbed miLung in the Journal of Thoracic Oncology. Hummingbird CSO Bruno Steinkraus said that the firm is very focused on early detection, even though its first foray into diagnostics was the development of a cancer immunotherapy response predictor.  “The [immunotherapy application] was more of a side project, but it was significantly easier to do,” he said. “With early detection, there...

READ MORE
Hummingbird Diagnostics Announces Publication of miLung Small RNA-Based Blood Test for Early Detection of Lung Cancer in the Journal of Thoracic Oncology

Proprietary small RNA signature (miLung)-based blood test may support early lung cancer detection in primary care settings Results also presented in a poster at ASCO 2023 July 11, 2023 03:00 AM Eastern Daylight Time22 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a publication in the Journal of Thoracic Oncology following a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection. The results of the study provide...

READ MORE
Hummingbird Diagnostics to Present Poster on miLung Small RNA-Based Blood Test at the ASCO 2023 Annual Meeting

June 23, 2022 08:00 AM Eastern Daylight Time HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection. Details of the poster presentation are as follows: Title: Early detection of lung cancer using small RNAs Presenting Author: Bruno Steinkraus, PhD, Chief Scientific Officer of Hummingbird Diagnostics Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology Abstract: #3035 Poster Board: #233 Location: Hall A Date/Time: June 3, 2023 from 8:00...

READ MORE
Clexio and Genetika+ announce partnership using proprietary antidepressant screening platform

Feb 06, 2023, 08:11 ET TEL AVIV and PETAH TIKVA, Israel, Feb. 6, 2023 /PRNewswire/ — As part of a shared commitment to bring better solutions for people suffering from depression, Clexio and Genetika+ are partnering to screen and characterize Clexio’s antidepressant pipeline using Genetika+’s iPSC-derived neurons platform. Genetika+’s platform encompasses >200 neuronal lines from depression patients with in-depth clinical and demographic characterization and multiple assessments over the course of 12 months, as well as proprietary multi-modal biomarker read-outs on these neurons. The Genetika+ platform allows, for the first time, assessment of the functional effects of drugs directly on human neurons, the key target cells...

READ MORE
1 2 3 9
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER